# A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

> **NCT05984277** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1200 (estimated)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Volrustomig
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05984277
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2028-04-24
- **Final completion:** 2029-03-23
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984277, "A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05984277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*